Terms: = Endocrine gland cancer AND PR, PGR, progesterone receptor
1693 results:
1. Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian cancer.
Seol A; Kim SI; Yoon HY; Lee M; Kim HS; Chung HH; Park NH; Song YS
In Vivo; 2024; 38(3):1338-1350. PubMed ID: 38688599
[TBL] [Abstract] [Full Text] [Related]
2. Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma.
Rupp L; Dietsche I; Kießler M; Sommer U; Muckenhuber A; Steiger K; van Eijck CWF; Richter L; Istvanffy R; Jäger C; Friess H; van Eijck CHJ; Demir IE; Reyes CM; Schmitz M
Front Immunol; 2024; 15():1378190. PubMed ID: 38629072
[TBL] [Abstract] [Full Text] [Related]
3. Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients.
Yuan H; Li N; Wu L; Yao H
J Ovarian Res; 2024 Apr; 17(1):70. PubMed ID: 38561819
[TBL] [Abstract] [Full Text] [Related]
4. [A Case Report of Metastatic Breast cancer with Peritoneal Metastasis and Massive Ascites Responding to CDK4/6 Inhibitor(Palbociclib)].
Yao S; Goi T; Takahashi M; Kono H; Yokoi S; Maeda H
Gan To Kagaku Ryoho; 2024 Feb; 51(2):214-216. PubMed ID: 38449417
[TBL] [Abstract] [Full Text] [Related]
5. Mesonephric-like adenocarcinoma of the ovary.
Yang Y; Zhao M; Jia Q; Tang H; Xing T; Li Y; Tang B; Xu L; Wei W; Zheng H; Shi R; Xia B; Chen J
J Ovarian Res; 2024 Mar; 17(1):57. PubMed ID: 38444000
[TBL] [Abstract] [Full Text] [Related]
6. Value of diffusion kurtosis MR imaging and conventional diffusion weighed imaging for evaluating response to first-line chemotherapy in unresectable pancreatic cancer.
Zhang Z; Zhang Y; Hu F; Xie T; Liu W; Xiang H; Li X; Chen L; Zhou Z
Cancer Imaging; 2024 Feb; 24(1):29. PubMed ID: 38409049
[TBL] [Abstract] [Full Text] [Related]
7. Clinicopathological pattern of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 over-expression of epithelial ovarian carcinomas in Nigeria.
Ajani MA; Lawan A; Oke T; Khramtsova G; Nwanji I; Salami A; Awolude O; Ebili H; Onwukamuche ME; Sveen E; Yoshimatsu T; Olopade OI
Afr Health Sci; 2023 Sep; 23(3):236-244. PubMed ID: 38357171
[TBL] [Abstract] [Full Text] [Related]
8. The management of uterine tumor resembling an ovarian sex cord tumor (UTROSCT): case series and literature review.
Lin J; Liu L; Wang L; Ma N; Zhang K; Xie N; Yu H; Deng S; Sun Y
World J Surg Oncol; 2024 Feb; 22(1):42. PubMed ID: 38310233
[TBL] [Abstract] [Full Text] [Related]
9. GAD2 Is a Highly Specific Marker for Neuroendocrine Neoplasms of the Pancreas.
Lennartz M; Benjamin Dünnebier N; Höflmayer D; Dwertmann Rico S; Kind S; Reiswich V; Viehweger F; Lutz F; Fraune C; Gorbokon N; Luebke AM; Hube-Magg C; Büscheck F; Menz A; Uhlig R; Krech T; Hinsch A; Burandt E; Sauter G; Simon R; Kluth M; Steurer S; Marx AH; Lebok P; Dum D; Minner S; Jacobsen F; Clauditz TS; Bernreuther C
Am J Surg Pathol; 2024 Apr; 48(4):377-386. PubMed ID: 38271200
[TBL] [Abstract] [Full Text] [Related]
10. A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer.
Cristea MC; Stewart D; Synold T; Ruel N; Mortimer J; Wang E; Jung A; Wilczynski S; Konecny GE; Eng M; Kilpatrick L; Han E; Dellinger T; Hakim A; Lee S; Morgan RJ; Wakabayashi MT; Frankel PH
Gynecol Oncol; 2024 Mar; 182():124-131. PubMed ID: 38262235
[TBL] [Abstract] [Full Text] [Related]
11. Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast cancer.
Tan TJ; Sammons S; Im YH; She L; Mundy K; Bigelow R; Traina TA; Anders C; Yeong J; Renzulli E; Kim SB; Dent R
Clin Cancer Res; 2024 Apr; 30(7):1240-1247. PubMed ID: 38236575
[TBL] [Abstract] [Full Text] [Related]
12. Case report: Interstitial implantation radiotherapy combined with immunotherapy and GM-CSF in oligometastatic platinum-resistant ovarian cancer.
Qin Y; Huang S; Tang J; Fan Y; Deng X; Guan P; Zhang Z; Wen Q; Li D
Front Immunol; 2023; 14():1329951. PubMed ID: 38235148
[TBL] [Abstract] [Full Text] [Related]
13. Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues.
Wong RW; Cheung ANY
Pathology; 2024 Mar; 56(2):214-227. PubMed ID: 38212229
[TBL] [Abstract] [Full Text] [Related]
14. Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.
Pavel M; Lahner H; Hörsch D; Rinke A; Denecke T; Koch A; Regnault B; Helbig D; Hoffmanns P; Raderer M
Oncologist; 2024 May; 29(5):e643-e654. PubMed ID: 38206830
[TBL] [Abstract] [Full Text] [Related]
15. Making "cold" tumors "hot"- radiotherapy remodels the tumor immune microenvironment of pancreatic cancer to benefit from immunotherapy: a case report.
Tong F; Sun Y; Zhu Y; Sha H; Ni J; Qi L; Gu Q; Zhu C; Xi W; Liu B; Kong W; Du J
Front Immunol; 2023; 14():1277810. PubMed ID: 38179049
[TBL] [Abstract] [Full Text] [Related]
16. ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells.
Bergonzini C; Gregori A; Hagens TMS; van der Noord VE; van de Water B; Zweemer AJM; Coban B; Capula M; Mantini G; Botto A; Finamore F; Garajova I; McDonnell LA; Schmidt T; Giovannetti E; Danen EHJ
J Exp Clin Cancer Res; 2024 Jan; 43(1):4. PubMed ID: 38163893
[TBL] [Abstract] [Full Text] [Related]
17. Clinical Significance of Multi-cancer Genome Profiling: Data from a Single Hospital in Japan.
Aoyama R; Nishikubo H; Kawabata K; Kanei S; Yamamoto Y; Nishimura S; Yashiro M
Cancer Genomics Proteomics; 2024; 21(1):79-87. PubMed ID: 38151295
[TBL] [Abstract] [Full Text] [Related]
18. P53 and TLR4 expression are prognostic markers informing progression free survival of advanced stage high grade serous ovarian cancer.
Bates M; Mullen D; Lee E; Costigan D; Heron EA; Kernan N; Barry-O'Crowley J; Martin C; Keegan H; Malone V; Brooks RD; Brooks DA; Logan JM; Martini C; Selemidis S; McFadden J; O'Riain C; Spillane CD; Gallagher MF; McCann A; O'Toole S; O'Leary JJ
Pathol Res Pract; 2024 Jan; 253():155020. PubMed ID: 38103365
[TBL] [Abstract] [Full Text] [Related]
19. Correlation of clinicopathological and prognostic characteristics between endometriosis-associated and primary ovarian cancer.
Wang H; Chen C; Wang D; Zhu Y; Chen P
BMC Cancer; 2023 Dec; 23(1):1210. PubMed ID: 38066448
[TBL] [Abstract] [Full Text] [Related]
20. Grading medullary thyroid carcinoma on fine-needle aspiration cytology specimens with the International Medullary Thyroid Carcinoma Grading System: A cytologic-histologic correlation.
Viswanathan K; Behrman DB; Lubin DJ
Cancer Cytopathol; 2024 Apr; 132(4):224-232. PubMed ID: 38062948
[TBL] [Abstract] [Full Text] [Related]
[Next]
